Clinical Quick Reference — Women-Specific Prevention Strategies
The 2011 update introduces a three-tier classification system for stratifying women's CVD risk and guiding intensity of prevention interventions. This framework emphasizes long-term CVD risk (not just 10-year risk) and incorporates pregnancy-related complications as risk markers.
| Risk Status | Criteria |
|---|---|
| High Risk |
• Clinically manifest CHD (MI, angina, PCI, CABG) • Cerebrovascular disease (stroke, TIA, carotid disease) • Peripheral arterial disease • Abdominal aortic aneurysm • Diabetes mellitus • Chronic kidney disease (eGFR <60) • 10-year predicted CVD risk ≥10% |
| At Risk |
• Cigarette smoking • Total cholesterol ≥200 mg/dL • HDL-C <50 mg/dL • SBP/DBP >80 mmHg • Sedentary lifestyle • Obesity (BMI ≥25) • Poor diet • Family history of premature CVD • Metabolic syndrome • Advanced subclinical atherosclerosis • Depression/stress • History of preeclampsia, GDM, or gestational HTN • Fasting glucose >100 mg/dL |
| Ideal CV Health |
• Total cholesterol <200 mg/dL (untreated) • SBP/DBP <120/80 mmHg (untreated) • Fasting glucose <100 mg/dL (untreated) • No smoking • Physical activity ≥150 min/week • BMI <25 kg/m² |
Use the Framingham Risk Score, ASCVD calculator, Lifetime ASCVD Risk, PREVENT-ASCVD, or SCORE2 to estimate CVD risk and guide intensity of prevention.
Advise all women not to smoke and to avoid environmental tobacco smoke. Provide counseling at each encounter, nicotine replacement, and pharmacotherapy (varenicline, bupropion) with follow-up support. 1
| Activity Level | Details |
|---|---|
| Minimum activity | Accumulate ≥150 min/week moderate-intensity aerobic exercise (e.g., brisk walking) or ≥75 min/week vigorous-intensity (e.g., jogging). Episodes of ≥10 min, spread throughout week. 1 |
| Additional benefit | Resistance/muscle-strengthening activities on ≥2 days/week involving all major muscle groups. 1 |
| Nutrient/Food | Target |
|---|---|
| Fruits & vegetables | ≥4.5 cups/day with variety. 1 |
| Fish & omega-3 | 2 times/week (especially oily fish). Dietary sources preferred over supplements. 1 |
| Whole grains & fiber | ≥30 g/day dietary fiber. Choose whole-grain, high-fiber foods. 1 |
| Sugar, salt, alcohol | Added sugars <5–6% of intake; sodium <1,500 mg/day; alcohol ≤1 drink/day. 1 |
| Saturated fat | <7% of total energy intake. 1 |
Women should maintain or achieve appropriate body weight through balanced physical activity, caloric intake, and formal behavioral programs when indicated. Target BMI <25 kg/m² or appropriate metrics for individual needs. 1
Comprehensive CVD risk-reduction regimen (cardiac rehab or physician-guided community exercise) is recommended for women with recent acute coronary syndrome, new-onset/chronic angina, recent cerebrovascular event, peripheral arterial disease, or current/prior heart failure symptoms (LVEF ≤35%). 1
Optimal BP: <120/80 mmHg through lifestyle approaches (weight control, physical activity, alcohol moderation, sodium restriction, DASH pattern). 1
| Clinical Scenario | BP Threshold & Recommendation |
|---|---|
| High-risk women (CVD, diabetes, CKD, eGFR <60) | Initiate when SBP ≥140 or DBP ≥90 mmHg (or ≥130/80 in diabetes/CKD). Goal <130/80 mmHg. 1 |
| At-risk women (no established CVD) | Pharmacotherapy for BP ≥140/90 mmHg unless contraindicated. Select agent: ACE-I, ARB, beta-blocker, diuretic, or CCB. 1 |
| Class | Indications & Notes |
|---|---|
| ACE-I / ARB | Preferred in diabetes, CKD, or systolic heart failure. 1 Contraindicated in pregnancy. |
| Beta-blockers | Beneficial post-MI or with systolic LV dysfunction/heart failure. 1 |
| Diuretics / CCBs | Effective for BP control; consider in combination. Thiazide diuretics are cost-effective. |
| Parameter | Optimal | Recommendation |
|---|---|---|
| LDL-C (high-risk) | <100 mg/dL | Lifestyle + LDL-lowering therapy to goal <100 mg/dL. Consider <70 in very high-risk women (recent ACS, multiple poorly controlled factors). 1 |
| HDL-C | >50 mg/dL | Promote via exercise and weight loss. Lifestyle-based increase preferred. |
| Triglycerides | <150 mg/dL | Encourage lifestyle; treat if elevated with low HDL-C or high CVD risk. |
| Population | Recommendation |
|---|---|
| High-risk (CVD or diabetes) | LDL-lowering therapy (statin ± ezetimibe ± niacin) with lifestyle to achieve <100 mg/dL. 1 |
| At-risk (multiple factors) | Useful if LDL ≥130 mg/dL and 10-year risk ≥10%. Consider if <130 with multiple factors. 2b |
| No CVD, LDL 190–250 | Useful if other risk factors exist; otherwise await lifestyle trial first. 2b |
High-risk women with elevated non-HDL-C: Non-HDL-C lowering (statin + ezetimibe ± niacin/fibrate) is useful when non-HDL >130 mg/dL despite LDL therapy. 2b
Isolated HTG with low HDL: Niacin or fibrate can be useful if HDL <50 or non-HDL remains >130 in high-risk women despite LDL therapy. 2b
In women with diabetes, lifestyle and pharmacotherapy can help achieve HbA1c <7% if accomplished without significant hypoglycemia. For many women, <8% may be appropriate. 2b
Women with diabetes should receive antihypertensive therapy if SBP ≥140 or DBP ≥90 mmHg (or ≥130/80). ACE-I or ARB preferred for renal protection. 1
All women with diabetes are high-risk and should receive LDL-lowering therapy (typically statin) to achieve <100 mg/dL. 1
Aspirin 75–325 mg/day should be used in high-risk women with diabetes unless contraindicated. 2b
| Population | Recommendation |
|---|---|
| High-risk (established CVD) | Aspirin 75–325 mg/day unless contraindicated. 1 |
| At-risk with diabetes | Aspirin 75–325 mg/day is reasonable unless contraindicated. 2b |
| At-risk healthy women | May be reasonable if BP controlled and benefit outweighs GI bleed/hemorrhagic stroke risk. 2b |
| Women <65 without CVD/diabetes | Low-dose aspirin NOT recommended for primary prevention. 3 |
Post-MI or heart failure: Should be used for ≤12 months post-MI (Class I) or ≥3 years in systolic HF (Class I) unless contraindicated. 1
Long-term in LV dysfunction: Should be used in women with systolic dysfunction or heart failure unless contraindications. 1
Other coronary/vascular disease: May be considered with normal LV function. 2b
Post-MI or systolic LV dysfunction: ACE-I should be used (unless contraindicated) after MI, in clinical heart failure (LVEF ≤40%), or with diabetes. 1
CKD/diabetes/HTN with LV dysfunction: ARB if ACE-I intolerant. 1
Caution: Contraindicated in pregnancy; use care in women of childbearing potential.
Aldosterone antagonists after MI are indicated in women without significant hyperkalemia, renal dysfunction, or hypotension who are on ACE-I and β-blocker with LVEF <40% and symptomatic heart failure. 1
| Complication | Associated CVD Risk & Management |
|---|---|
| Preeclampsia | Approximately doubled risk of ischemic heart disease, stroke, and VTE over 5–15 years post-pregnancy. Classify as "at risk." Offer enhanced CV prevention. Regular follow-up and risk factor screening postpartum essential. |
| Gestational Diabetes | Increased risk for type 2 diabetes (and associated CVD). Lifestyle interventions and screening for impaired glucose tolerance postpartum important. |
| Gestational Hypertension | Associated with increased future CVD risk. Counsel on lifestyle modifications and regular BP monitoring postpartum. |
Women who experience pregnancy complications should have careful postpartum monitoring:
Pregnant women with CV complications should be referred for specialized peripartum care, particularly those with preeclampsia or other complications.
| Condition | CVD Risk & Management |
|---|---|
| SLE | 5–10 fold higher CVD risk due to disease-related inflammation and traditional risk factors. Classify as "high risk" or "at risk." Intensive preventive therapies (statins, antihypertensives, aspirin if indicated). Screen regularly for subclinical atherosclerosis. |
| RA | Increased CVD morbidity/mortality. Aggressive CV prevention (lipid lowering, BP control, smoking cessation) and anti-inflammatory treatment of underlying condition important. |
Women with systemic autoimmune disease should be screened regularly for CV risk factors (BP, lipids, glucose, smoking) and considered candidates for intensive preventive therapies at lower thresholds.
Depression is associated with:
Chronic psychosocial stress, lack of social support, and economic hardship are associated with increased CVD risk in women. CV prevention programs should address these factors and provide resources for stress management and mental health services.
Use these calculators to guide risk stratification and treatment decisions in women's CVD prevention:
10-year and 30-year ASCVD risk estimation for primary prevention in women and men without prior CVD.
Estimate 10-year and lifetime CVD risk using Framingham and cohort data.
Traditional 10-year CHD risk score for women without prior MI or stroke — referenced in the guideline.
Estimate lifetime (to age 95) CVD risk in younger women to motivate preventive behavior change.
European 10-year CVD risk score for primary prevention in women and men.